MENLO PARK, Calif.--(BUSINESS WIRE)--SRI International, an independent nonprofit research and development organization, today announced a personalized medicine program to develop biomarkers for cancer. The SRI program is part of a multi-year collaboration with Pentax Corporation, a developer of optical electronic products and medical instruments. The ultimate goal is to develop medical diagnostic tools for therapeutic intervention in the treatment of cancer.
